Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide in SR-GI-GVHD
NCT04290429Phase 1Completed
- Sponsor
- University of Freiburg
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of teduglutide in graft-versus-host disease (GVHD), sponsored by University of Freiburg. Primary endpoint: Paneth cell numbers at 2 years. Started Dec 2017; status: completed.
02
Drugs
teduglutide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04290429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290429.